A trial of Insulet’s Omnipod 5 trial in children and adults showed improvements in time and range and hemoglobin A1c after three months of use compared to standard therapy.
Insulet Corporation announced results from the first pivotal study of the Omnipod 5 automated insulin delivery system that bode well for its expected launch of the device in the first half of 2021.
The Omnipod 5 is the world’s first tubeless wearable system that continuously adapts insulin delivery based on glucose levels and trends.
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.
Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.
